Ten Stocks Trending on Discord for Thursday September 22, 2022: SPRO, AVCT, SAVA, TSLA, MOHO, SONN, AAPL, FREY, LIDR, GSK
$AAPL
$AVCT
$FREY
$GSK
Computer Manufacturing
Technology
EDP Services
Technology
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/19/2024 | $211.00 → $202.00 | Neutral | MoffettNathanson | |
| 11/15/2024 | Buy → Hold | Deutsche Bank | ||
| 11/12/2024 | $53.00 → $39.50 | Buy → Hold | Jefferies | |
| 11/4/2024 | $300.00 → $275.00 | Buy | Loop Capital | |
| 11/1/2024 | $203.00 → $215.00 | Hold | Maxim Group | |
| 10/31/2024 | Buy → Neutral | Guggenheim | ||
| 10/25/2024 | $200.00 | Sector Weight → Underweight | KeyBanc Capital Markets | |
| 10/24/2024 | $120.00 → $125.00 | Underweight | Wells Fargo |
NEW YORK, Nov. 19, 2024 /PRNewswire/ -- SunCar Technology Group Inc. (NASDAQ:SDA), a leading innovator in cloud-based B2B auto services and auto e-insurance in China, is pleased to announce its inclusion in the NASDAQ Golden Dragon China Index, marking an important milestone in the Company's growth journey. The NASDAQ Golden Dragon China Index is a benchmark for tracking Chinese companies listed on U.S. exchanges, offering investors a window into the dynamic growth opportunities within China's economy, particularly in sectors like digital services, technology, new consumer markets, and clean energy. This prestigious index includes leading Chinese companies like Alibaba (NYSE:BABA), JD.com (
Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs Appointment initiates Cassava's commercial readiness strategy as the Company prepares for first Phase 3 topline data readout before year end 2024 AUSTIN, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced the appointment of Freda Nassif as Chief Commercial Officer, effective today. As a member of the Company's executive leadership team, Ms. Nassif will report to Richard "Rick" Barry, President and Chief Executive of Cas
TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab
4 - FREYR Battery, Inc. /DE/ (0001992243) (Issuer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
MoffettNathanson reiterated coverage of Apple with a rating of Neutral and set a new price target of $202.00 from $211.00 previously
Deutsche Bank downgraded GlaxoSmithKline from Buy to Hold
Jefferies downgraded GlaxoSmithKline from Buy to Hold and set a new price target of $39.50 from $53.00 previously
6-K - GSK plc (0001131399) (Filer)
6-K - GSK plc (0001131399) (Filer)
6-K - GSK plc (0001131399) (Filer)
For Immediate Release: September 17, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a draft guidance, “Integrating Randomized Controlled Trials for Drug and Biological Products into Routine Clinical Practice,” which, when finalized, will support the conduct of randomized controlled trials with streamlined protocols a
For Immediate Release: September 12, 2024 Today, the U.S. Food and Drug Administration authorized the first over-the-counter (OTC) hearing aid software device, Hearing Aid Feature, intended to be used with compatible versions of the Apple AirPods Pro headphones. Once installed and customized to the user’s hearing needs, the Hearing Aid Feature enables compatible versions of the AirPods Pro to serve as an OTC hea
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
3 - CASSAVA SCIENCES INC (0001069530) (Issuer)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)
SC 13G/A - AEye, Inc. (0001818644) (Subject)
SC 13G/A - GSK plc (0001131399) (Subject)
Apollo shines in major in-vehicle driving test with NVIDIA Plan to establish Apollo manufacturing line with LITEON in 2024 AEye, Inc. (NASDAQ:LIDR), a global leader in adaptive, high performance lidar solutions, today announced its results for the third quarter ended September 30, 2024. Quarterly Business Highlights Apollo met the NVIDIA DRIVE Hyperion specifications, paving way for platform integration Apollo samples shipped to OEMs; sets new long-distance performance standard of 1 kilometer Apollo manufacturing line planned with LITEON in 2024, quoting multiple OEMs New financial instruments extend cash runway; pave way to automotive mass production Management Comment
CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2024 financial results and provide an update on its business on Thursday, November 14, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments fo
FREYR Battery (NYSE:FREY) ("FREYR" or the "Company") has announced that the Company has entered into an agreement to acquire the U.S. solar manufacturing assets of Trina Solar Co Ltd. (SHA: 688599) ("Trina Solar"). The transaction is subject to certain customary conditions precedent, including receipt of certain third-party consents, completion of the preferred stock issuance to Encompass Capital Advisors LLC and internal reorganization to be completed by Trina Solar and is expected to close around year end 2024. Highlights The transaction is expected to close year end 2024 and creates a leading integrated U.S.-owned and operated solar technology company with a pathway for value enhancin
Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs Appointment initiates Cassava's commercial readiness strategy as the Company prepares for first Phase 3 topline data readout before year end 2024 AUSTIN, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced the appointment of Freda Nassif as Chief Commercial Officer, effective today. As a member of the Company's executive leadership team, Ms. Nassif will report to Richard "Rick" Barry, President and Chief Executive of Cas
TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today announced that it has reached a settlement with the U.S. Securities and Exchange Commission ("SEC") of negligence-based disclosure charges that resolve a previously-disclosed SEC investigation into statements made by the Company pertaining to the results of its 2020 Phase 2b clinical trial of simufilam and related matters. Two former senior employees of the Company also settled negligence-based disclosure charges brought by the SEC. Cassava, without admitting or denying the SEC's allegations, agreed to pay a mone
To gain an edge, this is what you need to know today. GDP Brings Buying Please click here for an enlarged chart of Invesco QQQ Trust Series 1 (NASDAQ:QQQ). Note the following: The chart shows a drop in QQQ. The drop in QQQ was triggered by speculative sentiment pulling back. As a reader of The Arora Report, you knew in advance that speculative sentiment could fall as a result of Tesla Inc (NASDAQ:TSLA) earnings. The chart shows that QQQ is approaching the support zone. RSI on the chart shows that QQQ is now oversold. Oversold markets tend to bounce. The chart shows that the volume was low on the selloff. This indicates a lack of conviction in selling. Especially hard hit in
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird increased Apple Inc. (NASDAQ:AAPL) price target from $200 to $240. Baird analyst William Power maintained an Outperform rating. Apple shares fell 0.1% to trade at $218.51 on Thursday. See how other analysts view this stock. Truist Securities raised the price target for ServiceNow, Inc. (NYSE:NOW) from $750 to $780. Truist Securities analyst Joel Fishbein maintained a Hold rating. ServiceNow shares gained 11.9% to trade at $817.75 on Thursday. See how other analysts view this stock. JP Morg
Honda Motor Co. (NYSE:HMC) will reduce its production of gasoline vehicles in China by 19% starting this October, marking a strategic shift toward electric vehicles. The Japanese automaker will cease operations of one production line at its joint venture Dongfeng Honda, which has an annual capacity of 240,000 units, beginning in November. Additionally, in October, GAC Honda, another of its facilities with a capacity of 50,000 units annually, will be completely shut down. These changes are part of Honda's effort to accelerate the “steady shift” to EVs, reported Bloomberg. Honda’s production capacity in China, currently around 1.5 million units, will see a reduction of 19% due to